标题 |
[高分] Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial
托吡酯与纳曲酮治疗酒精使用障碍的基因型分层双盲随机对照试验
相关领域
纳曲酮
托吡酯
酒精使用障碍
酒
双盲
酒精依赖
随机对照试验
医学
内科学
精神科
生物
安慰剂
敌手
癫痫
替代医学
受体
病理
生物化学
|
备注 |
需要2024年6月14日发布的更新版本
|
网址 | |
DOI | |
其它 |
期刊:American Journal of Psychiatry 作者:Kirsten C. Morley; Henry R. Kranzler; Natasha Luquin; Nazila Jamshidi; Claire Adams; et al 出版日期:2024-05-01 After the May 2024 issue went to press, the authors of the article “Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial” (Kirsten C. Morley, Ph.D., et al [doi: 10.1176/appi.ajp.20230666]) wished to add clarifying text to their article presentation. In the Abstract, Results, and Discussion, definitions of dosages for topiramate (maximum dosage of 200 mg/day), dosages for naltrexone (50 mg/ day), and for heavy drinking days (≥ four drinks for women, ≥ five drinks for men) were added.These updates were made to the online version of the article and the article was reposted on June 14, 2024 |
求助人 | |
下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
温馨提示:该文献已被科研通 学术中心 收录,前往查看
科研通『学术中心』是文献索引库,收集文献的基本信息(如标题、摘要、期刊、作者、被引量等),不提供下载功能。如需下载文献全文,请通过文献求助获取。
|